RCKT today
$2.39-$0.09 (-3.63%)close Nov 12, 2026Trend
DailyDowntrend (confirmed)
4 hourSymmetric Triangle
1 hourSymmetric Triangle
15 minExpanding
5 minDescending Triangle
Daily trend turns up above $5.45
Key levels
Resistance$3.03
Resistance$2.67
Support$2.37
Support$2.17
Latest news & SEC filings
SEC FilingRocket Pharmaceuticals, Inc. filed an insider trading report (Form 4)
EarningsRocket Pharmaceuticals Posts Q3 2026 Financials
All RCKT news →About Rocket Pharmaceuticals
Rocket Pharmaceuticals is a clinical-stage biotechnology company that develops gene therapies for rare and serious diseases. Its pipeline includes treatments for Fanconi anemia, leukocyte adhesion deficiency-I, pyruvate kinase deficiency, Danon disease, and arrhythmogenic cardiomyopathy. The company uses lentiviral and adeno-associated virus vectors to deliver genetic medicines. It operates in the United States and Europe, targeting patients with limited treatment options.
Based on the company's 10-K filed Feb 26, 2026.
Nasdaq · Healthcare
ROCKET PHARMACEUTICALS, INC. (RCKT)
What Is the Price Target for RCKT?
SEPT Low Target
$4.00
SEPT Mid Target
$9.00
SEPT High Target
$15.00
Analyst Consensus
$9.00
Is RCKT a Buy or Sell Right Now?
Thesis
- •SEC filings signal active product innovation — 1 new product/expansion keywords detected in 10-K. R&D investment stable.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for RCKT.
Start Free Trial →Is RCKT Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$8.82
12
Moat Score
NONE
1/9
Piotroski Score
-4.7
Altman Z-Score
What Is Smart Money Doing with RCKT?
Insider Signal
SELLING
0 buys / 13 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Shah Gaurav | officer | Buy | 76,490 | $129K | May 21, 2026 |
| Shah Gaurav | officer | Sale | 55,684 | $172K | May 21, 2026 |
| Shah Gaurav | officer | Sale | 2,409 | $7K | May 19, 2026 |
| Wilson Martin | officer | Sale | 662 | $2K | May 19, 2026 |
| Militello John | officer | Sale | 384 | $1K | May 19, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →RCKT Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
26.37%
FCF Growth YoY
11.7%
Revenue Trend
UNKNOWN
Dark Pool Trades for RCKT
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for RCKT, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 23:29:38 | $2.37 | 1,000 | $$2K | SELL |
| 21:00:27 | $2.39 | 2,286 | $$5K | BUY |
| 21:00:26 | $2.39 | 1,093 | $$3K | BUY |
| 20:59:49 | $2.39 | 1,200 | $$3K | SELL |
| 20:59:49 | $2.39 | 3,500 | $$8K | SELL |
5 dark pool trades shown · $$22K preview volume
Real-time institutional flow, block trades, and net positioning
Options Flow for RCKT
PREVIEWSEPT Investing provides real-time options flow tracking for RCKT, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| CALL | $2.5 | Dec 18 | 36 | $$30 | 1 | SWEEP |
1 options trades shown · 100% calls
Unusual activity, GEX levels, max pain, and dealer positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for ROCKET PHARMACEUTICALS, INC. (RCKT) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →RCKT — frequently asked questions
What is RCKT stock price today?
ROCKET PHARMACEUTICALS, INC. (RCKT) is at $2.39, down 3.63% (-$0.09) at the Nov 12, 2026 close.
Why is RCKT stock moving today?
Latest RCKT news — Nov 12, 2026: Rocket Pharmaceuticals, Inc. filed an insider trading report (Form 4) · Nov 12, 2026: Rocket Pharmaceuticals Posts Q3 2026 Financials
What is the RCKT price target?
The average analyst price target for RCKT is $9.00, ranging from $4 to $15, based on 6 analysts. Latest: Goldman Sachs upgrade on Oct 8, 2026.
What do analysts rate RCKT?
Analyst ratings for RCKT: 2 Buy, 4 Hold, 0 Sell — consensus Hold.
Did RCKT beat earnings?
RCKT last reported on Aug 10, 2026: EPS $1.08 vs $0.86 expected — a beat of 25.6%.
Does RCKT pay a dividend?
RCKT does not currently pay a dividend.
What are RCKT support and resistance levels?
Support: $2.37, $2.17. Resistance: $2.67, $3.03, $3.27.
What are insiders doing with RCKT?
Insider activity: SELLING, 0 buys and 13 sells in the last 90 days.
What is the latest news on RCKT?
Nov 12, 2026: Rocket Pharmaceuticals, Inc. filed an insider trading report (Form 4) · Nov 12, 2026: Rocket Pharmaceuticals Posts Q3 2026 Financials